

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**LIMITED REVIEW REPORT AND  
THE INTERIM CONDENSED  
SEPARATE FINANCIAL STATEMENTS  
FOR THE THREE MONTHS PERIOD ENDED  
31 MARCH 2026**

**CLEOPATRA HOSPITAL “S.A.E.”**

**Interim condensed separate financial statements  
For the three months period ended 31 March 2026**

---

<b>Index</b>	<b>Page</b>
Limited review report	1
Interim condensed separate statement of financial position	2
Interim condensed separate statement of profits or losses	3
Interim condensed separate statement of comprehensive income	4
Interim condensed separate statement of changes in equity	5
Interim condensed separate statement of cash flows	6
Notes to the interim condensed separate financial statements	7 - 24

## Limited Review Report on the Interim Financial Statements

To the Board of Directors of Cleopatra Hospital Company (S.A.E.)

### Introduction

We conducted our limited review on the accompanying interim condensed separate financial position of Cleopatra Hospital Company (S.A.E.) (the "Company") as at 31 March 2026 and the related interim condensed separate statements of profit or loss, comprehensive income, changes in equity and cash flows for the three months period then ended. The management is responsible for the preparation and fair presentation of these interim condensed separate financial statements in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting". Our responsibility is limited to express a conclusion on these interim condensed separate financial statements based on our limited review.

### Scope of the limited review

We conducted our limited review in accordance with the Egyptian Standard on Limited Review Engagements (2410), "Limited Review of Interim Financial Statements Performed by the Auditor of the Entity". A limited review of the interim condensed separate financial statements consists of applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with the Egyptian Standards on Auditing and consequently does not enable us to obtain an assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed separate financial statements.

### Conclusion

Based on our limited review, nothing has come to our attention which causes us to believe that the accompanying interim condensed separate financial statements are not prepared, in all material respects in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting".

  
Mohamed Elsawaf  
R.A.A. 39521  
F.R.A. 419




4 June 2026  
Cairo

**CLEOPATRA HOSPITAL COMPANY "S.A.E."**

**Interim condensed separate statement of financial position – At March 2026**

(All amounts are shown in Egyptian Pounds)	Note	31 March 2026	31 December 2025
<b>Assets</b>			
<b>Non-current assets</b>			
Fixed assets	5	1,087,405,589	1,062,514,854
Right-of-use assets	6	24,215,488	26,291,899
Goodwill		158,516,300	158,516,300
Investments in subsidiary	7	2,187,650,145	2,187,650,145
Investments in associates	8	2,449,990	2,449,990
<b>Total non-current assets</b>		<b>3,460,237,512</b>	<b>3,437,423,188</b>
<b>Current assets</b>			
Inventories	9	98,044,103	81,946,594
Trade and other receivables	10	517,399,920	469,313,147
Due from related parties	22	862,604,216	645,743,697
Debtors and other debit balances	11	90,196,608	85,972,829
Cash and cash equivalents	12	178,266,914	101,386,817
<b>Total current assets</b>		<b>1,746,511,761</b>	<b>1,384,363,084</b>
<b>Total assets</b>		<b>5,206,749,273</b>	<b>4,821,786,272</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Share capital		724,725,042	724,725,042
Retained earnings		1,798,068,943	1,665,304,584
Employees stock ownership Plan		49,049,246	32,699,497
Reserves		251,457,076	251,457,076
<b>Total equity</b>		<b>2,823,300,307</b>	<b>2,674,186,199</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Lease liabilities	16	20,933,087	23,218,690
Loans	13	244,125,000	264,000,000
Deferred tax liabilities		14,248,573	11,313,127
<b>Total non-current liabilities</b>		<b>279,306,660</b>	<b>298,531,817</b>
<b>Current liabilities</b>			
Borrowings	14	513,617,643	391,325,194
Provisions		52,572,334	61,527,892
Trade and other payables	15	596,916,162	544,338,154
Due to related parties	22	569,268,134	540,106,345
Loans	13	79,500,000	79,500,000
Lease liabilities	16	15,453,605	15,295,855
Employee incentive plan		95,931,762	73,961,551
Other liabilities		4,485,000	4,485,000
Current income tax liabilities		176,397,666	138,528,265
<b>Total current liabilities</b>		<b>2,104,142,306</b>	<b>1,849,068,256</b>
<b>Total liabilities</b>		<b>2,383,448,966</b>	<b>2,147,600,073</b>
<b>Total equity and liabilities</b>		<b>5,206,749,273</b>	<b>4,821,786,272</b>

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

  
Mr. Amr Al Rashid  
Chief Financial Officer

  
Dr. Ahmed Ezz El Dein Mahmoud  
CEO and Managing Director

  
Mr. Ahmed Adel Badr El dien  
Non-Executive Chairman of the  
Board of Directors

4 June 2026  
Limited review report is attached



**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Interim condensed separate statement of profit or loss  
For the three months ended 31 March 2026**

(All amounts are shown in Egyptian Pounds)	<u>Note</u>	<u>31 March 2026</u>	<u>31 March 2025</u>
Operating Revenue	17	703,936,830	600,001,546
<b>(Less):</b>			
Cost of revenue	18	(398,863,404)	(336,166,580)
<b>Gross profit</b>		<b>305,073,426</b>	<b>263,834,966</b>
<b>Add:</b>			
General and administrative expenses	19	(99,241,149)	(78,747,932)
Expected credit losses in financial assets	20	(7,232,358)	(6,009,593)
Other income		(2,812,146)	949,298
<b>Operating profit</b>		<b>195,787,773</b>	<b>180,026,739</b>
Finance income		14,845,856	4,607,010
Finance expenses		(37,064,423)	(27,840,530)
Consulting expenses for acquisition activities		-	(330,000)
<b>Profit before income tax</b>		<b>173,569,206</b>	<b>156,463,219</b>
Current tax		(37,869,401)	(35,357,146)
Deferred tax		(2,935,446)	(9,184,109)
<b>Net profit for the period</b>		<b>132,764,359</b>	<b>111,921,964</b>
<b>Earnings per share (Basic / Diluted)</b>	21	<b>0.09</b>	<b>0.08</b>

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Interim condensed separate statement of comprehensive income  
For the three months ended 31 March 2026**

---

(All amounts are shown in Egyptian Pounds)	<u>31 March 2026</u>	<u>31 March 2025</u>
Net profit for the period	132,764,359	111,921,964
Other comprehensive income	-	-
<b>Total comprehensive income for the period</b>	<b><u>132,764,359</u></b>	<b><u>111,921,964</u></b>

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Interim condensed separate statement of changes in equity - For the three months period ended 31 March 2026**

(All amounts in Egyptian Pounds)	Share capital	Treasury Shares	Reserves	Retained earnings	Employees stock ownership plan	Total equity
<b>Balance at 1 January 2025</b>	722,717,101	(5,589,873)	188,823,089	1,254,673,621	36,466,936	2,197,090,874
Employees stock ownership plan	-	-	-	-	30,000,000	30,000,000
Total comprehensive income for the period	-	-	-	111,921,964	-	111,921,964
<b>Balance at 31 March 2025</b>	<b>722,717,101</b>	<b>(5,589,873)</b>	<b>188,823,089</b>	<b>1,366,595,585</b>	<b>66,466,936</b>	<b>2,339,012,838</b>
<b>Balance at 1 January 2026</b>	724,725,042	-	251,457,076	1,665,304,584	32,699,497	2,674,186,199
Employees stock ownership plan	-	-	-	-	16,349,749	16,349,749
Total comprehensive income for the period	-	-	-	132,764,359	-	132,764,359
<b>Balance at 31 March 2026</b>	<b>724,725,042</b>	<b>-</b>	<b>251,457,076</b>	<b>1,798,068,943</b>	<b>49,049,246</b>	<b>2,823,300,307</b>

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Interim condensed separate statement of cash flows  
For the three months period ended 31 March 2026**

(All amounts in Egyptian Pounds)	Note	31 March 2026	31 March 2025
<b>Cash flows from operating activities</b>			
Profit before income tax		173,569,206	156,463,219
<b>Adjustments to settle net profit with cash flow from operating activities</b>			
Fixed assets depreciation	5	20,185,707	14,384,185
Right of use depreciation	6	2,488,037	2,246,757
Losses on disposal of fixed assets		-	(1,101,755)
Impairment of trade receivables	20	7,232,361	6,009,593
Impairment of inventories		379,987	3,950
Provisions		4,854,210	2,238,515
Interest and commission – Credit facilities		35,673,685	26,464,900
Interest and commission - Lease contracts	16	1,390,738	1,375,630
Interest income		(2,072,391)	(2,718,700)
Financial obligations for share - Based Payments		38,319,960	30,000,000
<b>Operating cash flows before changing in assets and liabilities</b>		<b>282,021,500</b>	<b>235,366,294</b>
<b>Changes in assets and liabilities</b>			
Changes in inventories		(16,477,496)	(11,978,963)
Changes in trade receivables		(54,498,692)	(43,163,635)
Changes in due from related parties		(216,860,519)	(15,645,758)
Changes in debtors and other debit balances		(4,223,779)	(4,730,560)
Changes in due to related parties		29,161,789	34,364,262
Changes in creditors and other credit balances		52,578,008	50,048,913
<b>Changes in working capital</b>		<b>71,700,811</b>	<b>244,260,553</b>
Provision used		(13,809,769)	(8,676,809)
<b>Net cash generated from operating activities</b>		<b>57,891,042</b>	<b>235,583,744</b>
<b>Cash flows from investing activities</b>			
Fixed assets purchase	5	(7,679,581)	(7,812,416)
Projects under construction purchase	5	(37,396,861)	(78,399,714)
Proceeds for sale of fixed assets		-	1,101,755
Interest received		2,072,391	2,718,700
Payments for acquisition of associates		-	(140,003,000)
<b>Net cash used in investing activities</b>		<b>(43,004,051)</b>	<b>(222,394,675)</b>
<b>Cash flows from financing activities</b>			
Banks overdraft		122,292,449	28,697,623
Loans		(19,875,000)	33,949,660
Payments of lease liabilities	16	(3,930,217)	(3,291,260)
Interest and commission paid		(35,673,685)	(26,464,900)
<b>Net cash generated from financing activities</b>		<b>62,813,547</b>	<b>32,891,123</b>
<b>Changes in cash and cash equivalents during the period</b>			
		<b>77,700,538</b>	<b>46,080,192</b>
Cash and cash equivalents at the beginning of the period		102,267,242	170,924,146
<b>Cash and cash equivalents at the end of the period</b>	12	<b>179,967,780</b>	<b>217,004,338</b>

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### 1. Introduction

Cleopatra Hospital Company (Lasheen and Partners) was established as a limited partnership on 19 July 1979 and is located in the Arab Republic of Egypt. The decision of the Chairman of Investment Authority No. 4092 of 2005 was issued on 27 June 2005 authorising the conversion of the legal type of Cleopatra Hospital (Lasheen and Partners) from a "limited partnership" into Cleopatra Hospital Company "S.A.E." in accordance with law no.95 of 1992.

The company is listed on the Egyptian Stock Exchange.

**Principal activity.** The Company's purpose is to establish a private hospital to provide advanced modern health and medical services, as well as the medical care of inpatients. The Company may have interest or participate in any manner in companies or other firms which carry on similar activities in Egypt or abroad. The Company may acquire, merge or affiliate such entities under the General Authority for Investment. The Separate financial statements representing in two Hospitals (Cleopatra Hospital and ElKateb Hospital)

**Registered address and place of business.** The Company is located at 39, 41 Cleopatra Street, Heliopolis, Cairo.

These independent financial statements of the Company were approved for issuance by the Board of Directors of the Company on 4 June 2026.

#### 2. Basis of preparation

##### 2.1 Compliance with Accounting Standards and Laws

These separate condensed interim financial statements for the three-month period ended March 31, 2026 have been prepared in accordance with Egyptian Accounting Standard No. 30, "Interim Financial Reporting".

These separate condensed interim financial statements do not include all disclosures normally provided in complete annual financial statements. Accordingly, they should be read in conjunction with the Company's separate annual financial statements as at December 31, 2025.

The results of operations for the three-month period ended March 31, 2026 are not necessarily indicative of the results expected for the financial year ending December 31, 2026.

The accounting policies applied in the preparation of these separate condensed interim financial statements are consistent with those applied in the preparation of the annual financial statements for the financial year ended December 31, 2025 and the comparative financial periods.

##### 2.2 Functional and presentation currency

Items included in the separate condensed interim financial statements are measured using the currency of the primary economic environment in which the Company operates (the functional currency). The Company's separate interim financial statements are presented in Egyptian Pounds, which is the Company's functional and presentation currency.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.”

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 2. Basis of preparation (continued)

##### 2.3 Use of Estimates and Judgments

The preparation of separate condensed interim financial statements requires management to apply judgments and make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues, and expenses. Actual results may differ from these estimates.

The significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty are the same as those described in the separate financial statements for the financial year ended December 31, 2025.

#### 3. Segment reporting

Business segments are reported in line with the reports provided internally to the senior management, which makes decisions related to resources allocation and evaluation of segments' performance in the Company. The senior management is represented in Company's executive management committee. The segment reports are provided to the Company based on each company, as each subsidiary is considered a separate business segment.

Below is a summary of each segment, which is presented for the period ended 31 March 2026 for each segment:

	<b>Cleopatra Hospital Company</b>	<b>Al Kateb Hospitals</b>	<b>Consolidated adjustment*</b>	<b>Total</b>
<u>Statement of financial position</u>				
Non-current assets	3,277,232,210	183,005,302	-	<b>3,460,237,512</b>
Current assets	1,705,044,132	116,038,023	(74,570,394)	<b>1,746,511,761</b>
<b>Total assets</b>	<b>4,982,276,342</b>	<b>299,043,325</b>	<b>(74,570,394)</b>	<b>5,206,749,273</b>
Current liabilities	2,062,596,363	116,116,337	(74,570,394)	<b>2,104,142,306</b>
Non-current liabilities	275,579,570	3,727,090	-	<b>279,306,660</b>
<b>Total Liabilities</b>	<b>2,338,175,933</b>	<b>119,843,427</b>	<b>(74,570,394)</b>	<b>2,383,448,966</b>
<u>Statement of profit or loss:</u>				
Operating revenue	623,399,935	80,536,895	-	<b>703,936,830</b>
Operating costs	(339,067,914)	(59,795,490)	-	<b>(398,863,404)</b>
<b>Gross profit</b>	<b>284,332,021</b>	<b>20,741,405</b>	-	<b>305,073,426</b>
Other expenses and revenues	(154,354,612)	(17,954,455)	-	<b>(172,309,067)</b>
<b>Profit for period</b>	<b>129,977,409</b>	<b>2,786,950</b>	-	<b>132,764,359</b>
<u>Other Items</u>				
Capital expenditure	44,088,675	987,768	-	<b>45,076,443</b>
Fixed assets depreciation	15,487,819	4,697,888	-	<b>20,185,707</b>

\* Consolidation constraints are mainly the exclusion of balances and transactions between CGUs.

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 3. Segment reporting (continued)

Below is a summary of each segment, which is presented for the year ended 31 December 2025 for each segment:

	<b>Cleopatra Hospital Company</b>	<b>Al Kateb Hospitals</b>	<b>Consolidated adjustment</b>	<b>Total</b>
<u>Statement of financial position</u>				
Non-current assets	3,253,157,921	184,265,267	-	3,437,423,188
Current assets	1,356,551,148	95,842,745	(68,030,809)	1,384,363,084
<b>Total assets</b>	<b>4,609,709,069</b>	<b>280,108,012</b>	<b>(68,030,809)</b>	<b>4,821,786,272</b>
Current liabilities	1,817,042,208	100,056,857	(68,030,809)	1,849,068,256
Non-current liabilities	294,893,610	3,638,207	-	298,531,817
<b>Total Liabilities</b>	<b>2,111,935,818</b>	<b>103,695,064</b>	<b>(68,030,809)</b>	<b>2,147,600,073</b>
<u>Statement of profit or loss:</u>				
Operating revenue	2,461,037,749	350,388,230	-	2,811,425,979
Operating costs	(1,280,600,614)	(238,794,303)	-	(1,519,394,917)
<b>Gross profit</b>	<b>1,180,437,135</b>	<b>111,593,927</b>	-	<b>1,292,031,062</b>
Other expenses and revenues	(660,423,352)	(75,720,022)	-	(736,143,374)
<b>Profit for period</b>	<b>520,013,783</b>	<b>35,873,905</b>	-	<b>555,887,688</b>
<u>Other Items</u>				
Capital expenditure	294,886,907	19,699,678	-	314,586,584
Fixed assets depreciation	58,841,356	10,681,534	-	69,522,890

\* Consolidation constraints are mainly the exclusion of balances and transactions between CGUs.

Below is a summary of each segment, which is presented for the year ended 31 March 2025 for each segment:

	<b>Cleopatra Hospital Company</b>	<b>Al Kateb Hospitals</b>	<b>Consolidated adjustment*</b>	<b>Total</b>
<u>Statement of financial position</u>				
Non-current assets	2,664,049,077	181,551,757	-	2,845,600,834
Current assets	1,094,968,032	87,268,168	(91,915,319)	1,090,320,881
<b>Total assets</b>	<b>3,759,017,109</b>	<b>268,819,925</b>	<b>(91,915,319)</b>	<b>3,935,921,715</b>
Current liabilities	1,224,250,725	114,239,787	(91,915,319)	1,246,575,193
Non-current liabilities	346,081,857	4,251,827	-	350,333,684
<b>Total Liabilities</b>	<b>1,570,332,582</b>	<b>118,491,614</b>	<b>(91,915,319)</b>	<b>1,596,908,877</b>
<u>Statement of profit or loss:</u>				
Operating revenue	525,216,305	74,785,241	-	600,001,546
Operating costs	(286,305,189)	(49,861,391)	-	(336,166,580)
<b>Gross profit</b>	<b>238,911,116</b>	<b>24,923,850</b>	-	<b>263,834,966</b>
Other expenses and revenues	(136,778,422)	(15,134,580)	-	(151,913,002)
<b>Profit for period</b>	<b>102,132,694</b>	<b>9,789,270</b>	-	<b>111,921,964</b>
<u>Other Items</u>				
Capital expenditure	76,799,599	9,412,531	-	86,212,130
Fixed assets depreciation	10,051,387	4,332,798	-	14,384,185

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Notes to the interim condensed separate financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**4. Financial assets and financial liabilities**

The Company holds the following financial instruments:

	<b>Amortized cost</b>	
	<b>31 March 2026</b>	<b>31 December 2025</b>
<b>Financial assets</b>		
Trade receivables	629,275,262	574,776,570
Due from related parties	862,604,216	645,743,697
Custodies	669,241	313,848
Cash on hand and at banks	178,933,866	100,750,945
	<b>1,671,482,585</b>	<b>1,321,585,060</b>

\* Excluding prepayments, advances to suppliers, and withholding taxes.

	<b>Amortized cost</b>	
	<b>31 March 2026</b>	<b>31 December 2025</b>
<b>Financial liabilities</b>		
Loans	323,625,000	343,500,000
Creditors and other credit balances **	591,120,150	544,338,154
Lease liabilities	36,386,692	38,514,545
Bank's overdraft	513,617,643	391,325,194
Due to Related Parties	569,268,134	540,106,345
Less: Cash and Cash equivalent	(179,967,780)	(102,267,242)
<b>Net Debt</b>	<b>1,854,049,839</b>	<b>1,755,516,996</b>
<b>Total equity</b>	<b>2,823,300,307</b>	<b>2,674,186,199</b>
<b>Total invested capital</b>	<b>4,677,350,146</b>	<b>4,429,703,195</b>
<b>Net debt to total invested capital</b>	<b>39.64%</b>	<b>39.63%</b>

\*\* Excluding social insurance.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements - For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

5. Fixed assets

	Lands	Machinery, equipment and devices	Tools and instruments	Furniture	Buildings	Vehicles	Computers	Leasehold improvements	Projects under construction	Total
<b>At 1 January 2025</b>										
Cost	82,878,000	329,609,998	24,895,501	41,100,487	241,927,626	37,534,595	66,741,558	43,821,468	281,888,587	1,150,397,820
Accumulated depreciation	-	(161,926,225)	(11,821,668)	(21,522,486)	(44,464,403)	(10,571,144)	(55,375,857)	(26,550,982)	-	(332,232,765)
<b>Net carrying amount</b>	<b>82,878,000</b>	<b>167,683,773</b>	<b>13,073,833</b>	<b>19,578,001</b>	<b>197,463,223</b>	<b>26,963,451</b>	<b>11,365,701</b>	<b>17,270,486</b>	<b>281,888,587</b>	<b>818,165,055</b>
<b>Year ended 31 December 2025</b>										
Net carrying amount at the beginning of the year	82,878,000	167,683,773	13,073,833	19,578,001	197,463,223	26,963,451	11,365,701	17,270,486	281,888,587	818,165,055
Additions	-	11,705,563	2,933,678	5,390,324	758,101	5,700,000	4,582,875	-	283,516,043	314,586,584
Disposals	-	(829,126)	(189,742)	(728,563)	-	(1,794,000)	(649,789)	-	(592,242)	(4,783,462)
Transferred from projects in progress	-	-	4,603,091	690,722	7,142,010	-	269,511	-	(12,705,334)	-
Depreciation for the year	-	(28,110,968)	(2,728,159)	(5,670,338)	(15,801,706)	(5,345,845)	(6,403,174)	(5,462,700)	-	(69,522,890)
Accumulated depreciation of disposals	-	829,126	189,742	606,910	-	1,794,000	649,789	-	-	4,069,567
<b>Balance at 31 December 2025</b>	<b>82,878,000</b>	<b>151,278,368</b>	<b>17,882,443</b>	<b>19,867,056</b>	<b>189,561,628</b>	<b>27,317,606</b>	<b>9,814,913</b>	<b>11,807,786</b>	<b>552,107,054</b>	<b>1,062,514,854</b>
<b>At 31 December 2025</b>										
Cost	82,878,000	340,486,435	32,242,528	46,452,970	249,827,737	41,440,595	70,944,155	43,821,468	552,107,054	1,460,200,942
Accumulated depreciation	-	(189,208,067)	(14,360,085)	(26,585,914)	(60,266,109)	(14,122,989)	(61,129,242)	(32,013,682)	-	(397,686,088)
<b>Net carrying amount at the end of the year</b>	<b>82,878,000</b>	<b>151,278,368</b>	<b>17,882,443</b>	<b>19,867,056</b>	<b>189,561,628</b>	<b>27,317,606</b>	<b>9,814,913</b>	<b>11,807,786</b>	<b>552,107,054</b>	<b>1,062,514,854</b>
<b>Year ended 31 March 2026</b>										
Opening net book value	82,878,000	151,278,368	17,882,443	19,867,056	189,561,628	27,317,606	9,814,913	11,807,786	552,107,054	1,062,514,854
Additions	-	1,503,145	100,149	48,906	-	-	6,027,381	-	37,396,861	45,076,442
Transfers from projects under construction	-	40,198,036	55,083,496	144,894	237,401,596	-	1,655,655	-	(334,483,677)	-
Depreciation for the period	-	(7,023,379)	(2,330,094)	(1,485,517)	(5,109,044)	(1,344,137)	(1,559,216)	(1,334,320)	-	(20,185,707)
<b>Balance at 31 March 2026</b>	<b>82,878,000</b>	<b>185,956,170</b>	<b>70,735,994</b>	<b>18,575,339</b>	<b>421,854,180</b>	<b>25,973,469</b>	<b>15,938,733</b>	<b>10,473,466</b>	<b>255,020,238</b>	<b>1,087,405,589</b>
<b>At 31 March 2026</b>										
Cost	82,878,000	382,187,616	87,426,173	46,646,770	487,229,333	41,440,595	78,627,192	43,821,464	255,020,238	1,505,277,381
Accumulated depreciation	-	(196,231,446)	(16,690,179)	(28,071,431)	(65,375,153)	(15,467,126)	(62,688,459)	(33,347,998)	-	(417,871,792)
<b>Net carrying amount at the end of the year</b>	<b>82,878,000</b>	<b>185,956,170</b>	<b>70,735,994</b>	<b>18,575,339</b>	<b>421,854,180</b>	<b>25,973,469</b>	<b>15,938,733</b>	<b>10,473,466</b>	<b>255,020,238</b>	<b>1,087,405,589</b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.”

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 6. Right-of-use assets

The Egyptian Standard No. (49) “Leasing Contracts” has been applied in two phases as follows:

The first stage relates to lease contracts that were subject to Law (95) for the year 1995 starting on or after 1 January 2019, which are lease contracts related to medical equipment and measured at the beginning of the contract at a value equal to the value of the lease obligations in addition to rental expenses and subsequently depreciated over the life of the lease contracts using the straight-line method.

The second phase represents lease contracts related to buildings that were subject to Law (95) for the year 1995 starting on or after 1 January 2021 and measured at a carrying amount as if the standard had been applied since inception of the lease but discounted using the lending rate to the lessee at the date of application, and it is subsequently depreciated over the life of the lease using the straight-line method.

	<u>31 March 2026</u>	<u>31 December 2025</u>
<b>Buildings</b>		
Beginning balance for the period/ year	26,291,899	31,343,663
Settlements	-	-
Additions for the period/ year	411,626	4,313,372
Depreciation for the period/ year	<u>(2,488,037)</u>	<u>(9,365,136)</u>
<b>Total</b>	<u><b>24,215,488</b></u>	<u><b>26,291,899</b></u>

Lease payments are discounted using the interest rate implicit in the lease. If this rate cannot be determined, the lessee’s borrowing rate is used, which is the rate that shall be paid by the lessee to borrow the funds needed for the acquisition of an equivalent value asset in a similar economic environment with similar terms and conditions. An average interest rate of 11.15% was used at initial recognition.

#### 7. Investments in subsidiaries

	<u>Investment Percentage</u>	<u>Country</u>	<u>31 March 2026</u>	<u>31 December 2025</u>
Investment in CHG SKY	99.99%	Egypt	1,050,000,000	1,050,000,000
Investments in Nile Badrawi Hospital Company	99.99%	Egypt	380,004,947	380,004,947
Investments in Al shorouk Hospital Company	99.99%	Egypt	374,142,000	374,142,000
Investments in Cairo Specialised Hospital Company	57.01%	Egypt	153,712,998	153,712,998
Investments in El Bedaya El Gedida for Medical Centers and Hospitals Company	60%	Egypt	119,482,000	119,482,000
Investment in Heaven Company	99.99%	Egypt	80,000,700	80,000,700
Investments in CHG for hospitals Company	99.99%	Egypt	30,000,000	30,000,000
Investments in CHG Pharma for Pharmacies Management Company	98%	Egypt	245,000	245,000
	20%			
Investments in CHG for Medical Services Company	(preferred shares)	Egypt	62,500	62,500
			<u><b>2,187,650,145</b></u>	<u><b>2,187,650,145</b></u>

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Notes to the interim condensed separate financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**8. Investments in associates:**

	<b>31 March 2026</b>	<b>31 December 2025</b>
Egypt Healthcare Facilities Services for facility management	2,449,990	2,449,990
	<b>2,449,990</b>	<b>2,449,990</b>

**9. Inventories**

	<b>31 March 2026</b>	<b>31 December 2025</b>
Medical supply inventory	57,133,810	44,149,181
Medicine inventory	37,830,124	33,321,903
Maintenance and spare parts inventory	2,148,772	2,619,283
Hospitality inventory	1,641,259	1,860,489
Stationary inventory	618,192	853,078
Food and beverage inventory	390,072	480,799
	<b>99,762,229</b>	<b>83,284,733</b>
Less: Impairment of inventory	(1,718,126)	(1,338,139)
	<b>98,044,103</b>	<b>81,946,594</b>

Movement in the provision for inventory is as follows:

	<b>31 March 2026</b>	<b>31 December 2025</b>	<b>31 March 2025</b>
<b>Balance at the beginning of the period/ year</b>	<b>1,338,139</b>	<b>425,920</b>	<b>425,920</b>
Provisions formed during the period/ year	379,987	912,219	3,950
<b>Balance at the end of the period/ year</b>	<b>1,718,126</b>	<b>1,338,139</b>	<b>429,870</b>

**10. Trade receivables**

	<b>31 March 2026</b>	<b>31 December 2025</b>
Due from customers	597,764,164	554,982,559
Income from inpatients	31,511,098	19,794,011
	<b>629,275,262</b>	<b>574,776,570</b>
<b>Less:</b>		
Impairment of customers' balances	(111,875,342)	(105,463,423)
	<b>517,399,920</b>	<b>469,313,147</b>

Revenue from inpatients includes revenue that has not been billed at the financial position date for their residency while the medical services' procedures have not been completed. This revenue is calculated after deducting the amounts collected in advance during their residency.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.”

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 10. Trade receivables (continued)

The Company applies the EAS 47 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

The expected loss rates are based on the payment profiles for customers over a period of 36 months before the date of each statement of financial position and corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the debit balances. The Group has identified the GDP and the unemployment rate in countries in which it sells its goods and services to be the most relevant factor, and accordingly adjusts the historical loss rates based on expected changes in these factors.

Credit loss provision for trade receivables is determined according to the provision matrix presented in the table below. The provision matrix is based on the number of days an asset is past due, while being adjusted.

Trade receivables	31 March 2026			
	Loss Rate	Gross carrying amount	Lifetime ECL	Net carrying value
Current until less than 30 days overdue	0.2%	303,210,138	618,982	302,591,156
30 to 60 days overdue	1%	102,611,826	1,182,114	101,429,712
61 to 90 days overdue	3%	37,421,135	1,243,218	36,177,917
91 to 120 days overdue	8%	20,006,939	1,595,383	18,411,556
121 to 360 days overdue	24%	63,558,890	15,121,981	48,436,909
361 to 720 days overdue	40%	12,411,983	4,933,752	7,478,231
More than 720 days	97%	90,054,351	87,179,912	2,874,439
<b>Total</b>		<b>629,275,262</b>	<b>111,875,343</b>	<b>517,399,920</b>

Trade receivables	31 December 2025			
	Loss Rate	Gross carrying amount	Lifetime ECL	Net carrying value
Current until less than 30 days overdue	0.2%	323,822,747	601,119	323,221,628
30 to 60 days overdue	1%	56,147,797	646,837	55,500,960
61 to 90 days overdue	3%	31,241,283	1,037,909	30,203,374
91 to 120 days overdue	8%	18,841,870	1,502,479	17,339,391
121 to 360 days overdue	25%	52,570,974	12,937,724	39,633,250
361 to 720 days overdue	41%	5,791,107	2,376,563	3,414,544
More than 720 days	100%	86,360,792	86,360,792	-
<b>Total</b>		<b>574,776,570</b>	<b>105,463,423</b>	<b>469,313,147</b>

The movement in expected credit losses in the value of trade receivables is as follows:

	31 March 2026	31 December 2025	31 March 2025
<b>Balance at the beginning of the period/year</b>	<b>105,463,423</b>	<b>59,638,363</b>	<b>59,638,363</b>
Provisions formed during the period/year	12,236,576	52,189,444	5,826,307
Provision no longer required during the period/year	(5,824,656)	(6,364,384)	-
	<b>111,875,342</b>	<b>105,463,423</b>	<b>65,464,670</b>

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Notes to the interim condensed separate financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**11. Debtors and other debit balances**

	<u>31 March 2026</u>	<u>31 December 2025</u>
Advances to suppliers	54,872,004	66,566,465
Prepaid expenses	27,993,652	12,474,001
Employee’s custodies	5,048,669	5,048,669
Deposits with others	669,241	313,848
Withholding taxes	629,413	543,450
Other debtors	983,629	1,026,396
	<u><b>90,196,608</b></u>	<u><b>85,972,829</b></u>

**12. Cash and cash equivalents**

	<u>31 March 2026</u>	<u>31 December 2025</u>
Time deposit	101,006,506	89,113,520
Current accounts	77,927,360	11,637,425
Cash on hand	1,033,914	1,516,297
<b>Deduct:</b>		
Expected credit losses in cash and cash equivalents	(1,700,866)	(880,425)
	<u><b>178,266,914</b></u>	<u><b>101,386,817</b></u>

Movement in the impairment is as follows:

	<u>31 March 2026</u>	<u>31 December 2025</u>	<u>31 March 2025</u>
Balance at the beginning of the period/ year	880,425	967,276	967,276
Formed during the period/ year	820,441	991,727	183,286
No longer required	-	(1,078,578)	-
<b>Ending balance</b>	<u><b>1,700,866</b></u>	<u><b>880,425</b></u>	<u><b>1,150,562</b></u>

The time deposits item includes an amount EGP 101,006,506 on 31 March 2026 (2025: EGP 89,113,520) are denominated in local banks in US dollars and are payable within one from the date of deposit and are subject to a fixed annual return of 3.75%.

Current accounts deposited in Egyptian Pounds are subject to a fixed annual rate of (15% to 16%), (2025: from 15% to 16%).

**Classification within cash and cash equivalents**

Term deposits with banks are held and presented as cash and cash equivalents if they mature within three months or less from the date of deposit and are repayable upon 24 hours’ notice without loss of interest. Treasury bills included under cash and cash equivalents have original maturities not exceeding three months from the acquisition date, are readily convertible into known amounts of cash, and are subject to an insignificant risk of changes in value.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.”

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 12. Cash and cash equivalents (continued)

The Company's cash and bank balances are maintained with reputable financial institutions holding credit ratings ranging from B3 to CAA1 as assigned by Moody's Corporation and S&P Global.

For the purpose of preparing the statement of cash flows, cash and cash equivalents comprise:

	<u>31 March 2026</u>	<u>31 December 2025</u>
Cash and cash equivalents before deduction of expected credit losses.	179,967,780	217,004,338
	<u>179,967,780</u>	<u>217,004,338</u>

#### 13. Loans

<b>31 March 2026</b>	<u>Current</u>	<u>Non-current</u>	<u>Total</u>
Loans	79,500,000	244,125,000	323,625,000
<b>Total</b>	<u>79,500,000</u>	<u>244,125,000</u>	<u>323,625,000</u>
<b>31 December 2025</b>	<u>Current</u>	<u>Non-current</u>	<u>Total</u>
Loans	79,500,000	264,000,000	343,500,000
<b>Total</b>	<u>79,500,000</u>	<u>264,000,000</u>	<u>343,500,000</u>

- On 27 October 2021, Cleopatra Hospital Company signed a contract for a medium-term loan with Kuwait Fund House, with a total amount of EGP 145 million, with a return of 0,65%, in addition to the lending rate announced by the Central Bank of Egypt.
- On 10 August 2022, Cleopatra Hospital Company, Nile Badrawy Hospital Company, and Cairo Specialized Hospital Company signed an appendix to the loan contract from Kuwait Fund Bank. The following are the most significant contracting terms:
- Increasing the financing amount to EGP 285 million, and it will be divided among the companies as follows:

Cleopatra Hospital Company	EGP 45 million
Cairo Specialized Hospital Company	EGP 90 million
Nile Badrawy Hospital Company	EGP 150 million

On 10 May 2023, the financing amount was redivided among the companies as follows, provided that the maximum amount of financing available amounts to EGP 340 million, and the aforementioned amount shall not be exceeded at any time throughout the contract period.

Cleopatra Hospital Company	EGP 100 million
Cairo Specialized Hospital Company	EGP 90 million
Nile Badrawy Hospital Company	EGP 150 million

On 18 January 2024, the financing amount was redivided among the companies as follows, provided that the maximum amount of financing available amounts to EGP 740 million, and the aforementioned amount shall not be exceeded at any time throughout the contract period.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.”

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### 13. Loans (continued)

Cleopatra Hospital Company	EGP 500 million
Cairo Specialized Hospital Company	EGP 90 million
Nile Badrawy Hospital Company	EGP 150 million

On 17 April 2024, the financing amount was redivided among the companies as follows, provided that the maximum amount of financing available amounts to EGP 740 million, and the aforementioned amount shall not be exceeded at any time throughout the contract period.

Cleopatra Hospital Company	EGP 400 million
Cairo Specialized Hospital Company	EGP 90 million
Nile Badrawy Hospital Company	EGP 250 million

- The purpose of the loan is to finance and/or refinance the capital needs and refurbishment of the group's hospitals starting from 2021, including medical equipment, medical and non-medical beds, medical and non-medical furniture, as well as the internal development of movable assets (finishes, electromechanical equipment, and the power station).
- This contract shall take effect for a period of six years and six months from the date of signing the finance contract on 27 October 2021, with the group being granted a period of availability of a maximum of one year and six months ending on 31 December 2023, and a grace period (applied to payment of the asset) of one year and six months ending on 31 January 2024, and in the event that the entire financing amount is not withdrawn during the aforementioned availability period, the unwithdrawn portion will be automatically cancelled and the bank is not obligated to lend the Group any other amounts other than what has been withdrawn from the financing amount, with the exception of the third tranche belonging to Cleopatra Hospital Company, which amounts to 400 million Egyptian pounds, the withdrawal period is two years starting from the date of signing the contract, with a grace period of 18 months from the date of the first withdrawal from the tranche.
- The company is committed to paying the total financing amounting to 397,500,000 EGP in 20 quarterly instalments, Starts from January 2024 for the first trench amounting to EGP 97.500,000 EGP in January 2024 to October 2028, while the first installment of the second loan, amounting to 300,000,000 Egyptian pounds, will be due in October 2025 and will be available until July 2030.

#### (a) Financial ratios

According to the contract terms, the Company shall achieve the following financial ratios:

- The financial leverage of the Company shall not exceed 1.6.
- Debt service rate should not fall below 1.
- Liquidity rate should not fall below 1 starting from 31 December 2026.

Loans contain certain covenants. Breaching of these covenants in the future may lead to renegotiation. The administration monitors covenants, and in the event of a potential breach, the administration takes the necessary measures to ensure compliance. Financial ratios are calculated starting from 31 December 2026, and there are no past due payments.

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Notes to the interim condensed separate financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**14. Banks overdraft**

	<b>31 March 2026</b>	<b>31 December 2025</b>
Banks overdraft	513,617,643	391,325,194
	<b>513,617,643</b>	<b>391,325,194</b>

The Company has obtained total credit limits in the form of bank overdrafts to finance working capital at an interest rate of 0.1% in addition to the lending rate announced by the Central Bank of Egypt. The total available credit limits amounted to EGP 530 million and the used amount of these credit limits at 31 March 2026 amounted to EGP 513,617,643 (EGP 391,325,194 at 31 December 2025).

**15. Trade and other payables**

	<b>31 March 2026</b>	<b>31 December 2025</b>
Suppliers and notes payable	314,488,998	263,102,437
Accrued expenses	256,478,067	252,673,438
Social insurance	5,796,012	5,008,889
Other creditors	20,153,085	23,553,390
	<b>596,916,162</b>	<b>544,338,154</b>

**16. Lease liabilities**

The weighted average incremental borrowing rate applicable to lease commitments recognized on 1 January 2021 was 11.15%.

The lease liabilities represent the present value of the lease obligations related to medical equipment that one of the Company obtained in exchange for lease contracts and lease contracts for buildings, and it was measured at the present value of the contractual lease payments discounted at an implied rate of return.

The following represents the undiscounted amount of obligations:

	<b>31 March 2026</b>	<b>31 December 2025</b>
<b>Undiscounted</b>		
During period / the year	23,458,150	15,295,855
More than period / a year	35,661,674	35,297,641
	<b>59,119,824</b>	<b>50,593,496</b>
<b>The present value of the lease obligations is as follows:</b>		
During period / the year	15,453,605	15,295,855
More than a year	20,933,087	23,218,690
<b>Balance</b>	<b>36,386,692</b>	<b>38,514,545</b>

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Notes to the interim condensed separate financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**16. Lease liabilities (continued)**

Lease Liabilities were presented as follows:

	<b>31 March 2026</b>	<b>31 December 2025</b>
<b>Lease liabilities shown as at 31 December 2025</b>	<b>38,514,545</b>	<b>42,906,489</b>
Additions during the period / year	411,626	4,313,372
<b>Add:</b> Interest formed during the period / year	1,390,738	5,580,675
<b>Deduct:</b> Payments during the period / year	(3,930,217)	(14,285,991)
<b>Lease liabilities at 31 March 2026</b>	<b>36,386,692</b>	<b>38,514,545</b>

**17. Operating revenue**

	<b>31 March 2026</b>	<b>31 March 2025</b>
Accommodation and medical supervision revenue	162,156,399	138,073,813
Surgeries revenue	109,363,249	101,969,948
Laboratories revenue	85,621,325	61,595,280
Radiology revenue	64,012,211	52,392,366
Outpatient clinics revenue	54,780,836	54,691,492
Pharmacy revenue	52,472,780	47,129,711
Service charge revenue	51,643,123	44,431,052
Cardiac catheterization revenue	50,380,552	32,422,077
Emergency revenue	35,969,184	33,068,848
Cardiac tests revenue	10,655,217	8,315,169
Physiotherapy revenue	10,370,208	9,356,430
Endoscopy revenue	6,091,130	5,597,072
Dentistry revenue	3,594,554	3,618,202
Other sections revenue	6,826,062	7,340,086
	<b>703,936,830</b>	<b>600,001,546</b>

\* Service charge” does not represent a separate performance obligation but is a surcharge at a fixed percentage rate applied to all revenue streams except for sale of medicines.

All types of revenue are recognized at a point in time except accommodation and medical supervision are recognized over time.

Timing of revenue recognition (for each revenue stream) is as follows:

	<b>31 March 2026</b>	<b>31 March 2025</b>
At a point in time	541,780,431	461,927,733
Over time -Accommodation and medical supervision revenue	162,156,399	138,073,813
	<b>703,936,830</b>	<b>600,001,546</b>

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Notes to the interim condensed separate financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**18. Operating costs**

	<b>31 March 2026</b>	<b>31 March 2025</b>
Doctors' fees	150,729,341	128,527,293
Salaries, wages and benefits	107,972,985	91,625,417
Medical and pharmaceutical supplies	79,796,324	72,335,970
Fixed assets depreciation	15,949,076	10,870,189
Maintenance, spare parts and energy expenses	13,500,845	13,813,556
Services from others	10,253,341	8,218,249
Consumables costs	8,151,704	7,707,538
Right of use depreciation	458,975	400,307
Other expenses	18,966,904	9,223,494
<b>(Less):</b> The Group's share of the Company's expenses	<b>(6,916,091)</b>	<b>(6,555,433)</b>
	<b><u>398,863,404</u></b>	<b><u>336,166,580</u></b>

**19. General and administrative expenses**

	<b>31 March 2026</b>	<b>31 March 2025</b>
Salaries, wages and benefits	109,935,659	86,086,588
Services from others	7,789,496	5,770,980
Professional and consulting fees	5,424,379	4,059,387
Fixed assets depreciation	4,236,631	3,513,996
Maintenance, spare parts and energy expenses	2,580,990	1,761,054
Right of use depreciation	2,029,062	1,846,450
Consumables costs	1,362,726	555,535
Other expenses	28,083,583	20,734,402
<b>(Less):</b> The Group's share of the Company's expenses	<b>(62,201,377)</b>	<b>(45,580,460)</b>
	<b><u>99,241,149</u></b>	<b><u>78,747,932</u></b>

**20. Expected credit losses in financial assets**

	<b>31 March 2026</b>	<b>31 March 2025</b>
Expected credit losses in trade receivables	6,411,917	5,826,307
Expected credit losses in cash at banks	820,441	183,286
	<b><u>7,232,358</u></b>	<b><u>6,009,593</u></b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.”

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 21. Earnings per share

The basic share of the profit for the year is calculated by dividing the net profit for the year attributable to the company’s shareholders by the weighted average number of shares outstanding during the year after excluding employee dividends.

	<u>31 March 2026</u>	<u>31 March 2025</u>
Distributable profit	<u>132,764,359</u>	<u>111,921,964</u>
Weighted average for number of shares	1,447,151,301	1,441,509,083
The weighted average number of ordinary shares for the purpose of the ESOP	<u>2,298,783</u>	<u>2,298,783</u>
<b>Weighted average number of ordinary shares for diluted earnings per share purposes</b>	<u>1,449,450,084</u>	<u>1,443,807,866</u>
<b>Earnings per share - Basic</b>	<u>0.09</u>	<u>0.08</u>
<b>Earnings per share - Diluted</b>	<u>0.09</u>	<u>0.08</u>

The weighted average number of shares is adjusted to take into account the shares held under the bonus and incentive scheme for employees, directors and executive board members.

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

**Notes to the interim condensed separate financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**22. Related parties From / To transactions**

During the period/ year the Company made transactions with certain related parties. The Balances with related parties at the financial statements date as well as the transactions during the year were as follows:

**Balances of financial position**

<b>(Related parties)</b>	<b>Transaction value</b>	<b>Balance due From (to) related parties 31 March 2026</b>	<b>Balance due From (to) related parties 31 December 2025</b>
CHG Sky Hospital (Subsidiary)	196,837,107	689,744,596	492,907,489
Cleopatra Heaven Company (Subsidiary)	14,334,687	134,179,674	119,844,987
CHG for Medical Service (Subsidiary)	1,956,643	36,900,911	34,944,268
CHG Pharma for Pharmacies Management (Subsidiary)	669,901	1,522,845	852,944
Other parties	-	256,190	256,190
Nile Badrawy Hospital (subsidiary)	(6,177)	(3,068,357)	(3,062,180)
Cairo Specialized Hospital (Subsidiary)	(27,428,942)	(247,527,113)	(220,098,171)
Al Shorouk Hospital (subsidiary)	(1,643,581)	(274,148,042)	(272,504,461)
CHG for Medical Service (Subsidiary)	513,377	(18,177,868)	(18,691,245)
New Bedayya for management of medical centres and Hospitals	2,465,715	(26,346,754)	(28,812,469)
		<b>293,336,082</b>	<b>105,637,352</b>

- During 2017, Cleopatra Hospital Company signed an agreement with its subsidiaries. Under this contract, the company distributes the costs of joint activities to the group companies according to the percentages related to the revenues achieved by each company.
- This agreement has been approved by the boards of directors of the group companies and their general assemblies.
- The transactions with the related parties are the Group's dealings with the parent company, whether by buying, selling or exchanging services. Prices, policies and conditions related to these operations are approved by the Group's management and are on the same basis as dealing with others.

## CLEOPATRA HOSPITAL COMPANY "S.A.E."

### Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### 23. Tax position

##### **First: Commercial and industrial profits tax**

- 1- The inspection was made until 2019, and the settlement & full payment were made.
- 2- years 2020. The inspection was done, we received Form 19 tax, the differences were paid, and the settlement is under settlement.
- 3- The years 2021 and 2022 are being examined.
- 4- The tax return from 2023 to 2025 has been submitted

##### **Second: Work gain tax**

- 1- The inspection was made till 31 December 2019, and the settlement and the full payment were made.
- 2- In 2020, the inspection was carried out, the 38 salary form was notified, and the original tax and remaining late fines were paid.
- 3- The years 2021 and 2022 were examined on the tax system and payment was made.
- 4- Salaries tax and form 4 tax for the year 2023 to date were submitted on the legally specified dates.

##### **Third: Stamp tax**

- 1- The inspection took place from August 1, 2006 to December 31, 2013, and the settlement was made in full.
- 2- The years 2014/2020 were examined, and a 19-stamp form was notified on 30 December 2021, and the differences were paid.
- 3- Years 2021 and 2022 are currently under review.

##### **Fourth: Value added tax**

- 1- It was examined until December 31, 2004.
- 2- The sales tax for the years 2005 to 2015 was examined and paid.
- 3- The company's registration was amended as of September 8, 2016, under registration number -240 893 204 - affiliated with the Major Financiers Office.
- 4- Tax returns from January 2015 to date have been submitted monthly on the legal dates.
- 5- The years from 2016 to 2019 were examined, and the tax differences were approved and paid.
- 6- The year 2020 was examined, the original tax was paid, and the additional tax remaining still to be paid.
- 7- The years 2021-2022 were inspected, and the inspection differences were paid.

#### 24. Capital commitments:

Capital commitments at financial year end, which are not yet due, amounted to EGP 849,931 (2025: EGP 120,850,038). Which represents capital commitments to purchase fixed assets and projects under construction.

## **CLEOPATRA HOSPITAL COMPANY “S.A.E.”**

### **Notes to the interim condensed separate financial statements For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### **25. Significant and Subsequent events**

##### **25.1 A settlement agreement regarding the land of the Nile Badrawi Hospital**

On February 13, 2020, the Cleopatra Hospital Company, the General Authority for River Transport, the Nile Badrawi Hospital Company, and the heirs of Engineer Hassan Badrawi signed a comprehensive and final settlement agreement, according to which it was agreed to resolve, settle, and end all disputes and claims related to the land on which the Nile Badrawi Hospital was built. The total settlement amounted to 36 million pounds, noting that part of the settlement falls within the limits of the amounts deducted from the selling price of Nile Badrawi Hospital shares in favor of Cleopatra Hospital. Concerning the land subject to settlement. On March 31, 2021, the Administrative Court issued a ruling accepting the case in form and rejecting it in substance. Cairo Governorate and the Nile Badrawi Hospital Company appealed the aforementioned ruling before the Supreme Administrative Court, and a session was set for September 21, 2022, so that both parties submit settlement contracts drawn up between the parties. The consideration of the appeal has been adjourned to a session on February 7, 2024, to take measures for the intervention of the heirs of the late Hassan Badrawi, and to review and review notes for whomever he wants. The consideration of the appeal has been postponed to a session on May 20, 2025 for final decision. Subsequently, the ruling was postponed to 25 November 2025, and further adjourned to 31 August 2026 for the submission of the settlement agreement.

##### **25.2 Impact of Military Conflict**

On 28 February 2026, the United States and Israel entered into a direct military confrontation with Iran. This conflict has also resulted in military engagements involving certain Gulf countries. These events are expected to have a significant economic impact on the global economy, particularly in the Middle East region. Management is closely monitoring ongoing developments to assess the potential impact of these events on the Company.